A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

Inclusion Criteria

• •Must have a confirmed diagnosis of moderate-to-severe plaque psoriasis requiring systemic treatment
• •Participants who are currently treated with Ustekinumab (either the originator or its biosimilar) and who are medically indicated to switch to Guselkumab
• •Participants who, based on the Investigator's decision, should initiate treatment with Guselkumab
• •Participants must understand and be willing and able to answer patient-reported outcomes (PROs)
• •Must sign an informed consent form (ICF) allowing data collection and source data verification in accordance with local requirements